市場調查報告書

全球高通量篩檢市場:成長,趨勢,預測

High-throughput Screening Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391482
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
全球高通量篩檢市場:成長,趨勢,預測 High-throughput Screening Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 115 Pages
簡介

本報告提供全球高通量篩檢市場相關調查,市場趨勢與今後的成長預測,各技術、各用途、各產品、各終端用戶、各地區的趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 波特五力分析

第6章 促進要素,阻礙要素,機會,課題分析

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各技術
    • 超高通量篩檢
    • 細胞化驗分析
    • 實驗室晶片
    • 免標定技術
    • 生物資訊學
  • 各用途
    • 標的確認
    • 初步篩檢
    • 毒性額
    • 肝細胞生物學
  • 各產品
    • 設備
    • 消耗品/試劑
    • 軟體、服務
    • 配件
    • 化驗
  • 各終端用戶
    • 醫藥品
    • 生物科技
    • 學術、政府機關
    • CRO
  • 各地區

第8章 各地區市場:各地區佔有率與預測

  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲
  • 南美

第9章 競爭環境

  • 合併、收購
  • 新產品上市
  • 協定,聯合,聯盟

第10章 企業簡介

第11章 分析師對投資機會的預測

第12章 市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 47198

Market Overview

The high-throughput screening market is expected to register a CAGR of 7.8%, during the forecast period. North America dominates the market, owing to large spending on pharmaceutical R&D and high adoption of high-throughput screening technology in drug discovery.

The high-throughput screening (HTS) centers in the public domain have increased significantly over the past decade, ranging in size, from modestly-equipped academic screening centers to well-endowed molecular libraries probe centers network (MLPCN). These centers facilitate a comprehensive approach to probe discovery in academia, and utilize, both, standard and innovative assay technologies for executing primary and secondary screening campaigns. One of the significant advantages of these centers was knowledge sharing among scientists, researchers, etc. In European countries, EU-open-screen, European counterpart of US NIH initiative, is also working to get open access to all European organizations involved in chemical biology. Additionally, the association of HTS centers is also emerging, which is aimed at sharing valuable information about the compound or target, or the whole process. The open access provides a better platform for knowledge sharing, and can help optimize the entire process, which may drive the demand for HTS technology among end users.

HTS systems allow tens of thousands or even hundreds of thousands of compounds to be evaluated in a single day. As the throughput increases, the amount of data for each experiment increases, and scientists analyze and derive results from large amounts of data. Due to the sheer number of samples being processed and the massive volume of data being produced, the need for extensive automation techniques arises, to streamline the operations. However, automation requires massive investments for the establishment of machinery and supporting architecture, which are roadblocks for small- and moderate-size research institutes. Thus, the high costs associated with automation techniques can limit the market expansion.

Scope of the Report

The high-throughput screening market has been segmented by technology, applications, products and services, end user, and geography. By technology, the market is divided into an ultra-high-throughput screening, cell-based assays, lab-on-a-chip, and label-free technology. By application, the market has been subdivided into target identification, primary screening, and toxicology. By products and services, the market has been segmented into instruments, reagents and kits, and services. By end user, the market has been segmented into pharmaceutical and biotechnology firms, academia and research institutes, and contract research organizations.

Key Market Trends

Pharmaceutical and Biotechnology Firms Represent the Largest End Users of High-throughput Screening Modalities.

In order to gain sustainable competitive advantage, most of the large and small biotechnology and pharmaceutical companies are focusing on the development of novel molecules for the treatment of several chronic conditions. The need for rapid and precise screening of several target molecules, during drug discovery and development phases, has led to the adoption of automated high-throughput screening techniques to screen massive chemical and biomarker libraries generated during the research processes. Since an automated HTS system can test 10,000 to 100,000 target compounds per day, and uHTS can test more than 100,000 compounds per day, their adoption for drug discovery and development process has resulted in the market expansion.

North America is Expected to Dominate the Market

North America dominates the global high-throughput screening market, owing to the high adoption rate of HTS in the United States. The growth of the US high-throughput screening market can be attributed to the significant advances in combinatorial chemistry and the field of genomics. In addition, huge investments by the pharmaceutical industry, for HTS technologies, in terms of automation, miniaturization, and assay methodology, have further helped in the growth of the market. Furthermore, the end users of this market have witnessed increasing numbers of leads, clinical candidates, and marketed drugs arising from high-throughput screening.

Competitive Landscape

The high-throughput screening market is highly competitive and consists of several major players. Most of the major players enjoy a global presence, and are facing intense competition in emerging economies. The emerging countries are becoming hotspots of significant competition, due to a rapidly expanding market size, fueled by growing investments in R&D and the recent trend of contract research outsourcing.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Open Access to High-throughput Screening Laboratories
    • 4.2.2 Technological Advancements in HTS
    • 4.2.3 Increasing Usage in Universities and Research Centers
  • 4.3 Market Restraints
    • 4.3.1 High Capital Investment
    • 4.3.2 Need for Extensive Automation Techniques
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 Ultra-high-throughput Screening
    • 5.1.2 Cell-based Assays
    • 5.1.3 Lab-on-a-chip
    • 5.1.4 Label-free Technology
  • 5.2 By Applications
    • 5.2.1 Target Identification
    • 5.2.2 Primary Screening
    • 5.2.3 Toxicology
  • 5.3 By Products and Services
    • 5.3.1 Instruments
    • 5.3.2 Reagents and Kits
    • 5.3.3 Services
  • 5.4 By End Users
    • 5.4.1 Pharmaceutical and Biotechnology Firms
    • 5.4.2 Academia and Research Institutes
    • 5.4.3 Contract Research Organizations
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 US
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 UK
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies Inc.
    • 6.1.2 Axxam SpA
    • 6.1.3 Beckman Coulter Inc.
    • 6.1.4 Bio-Rad Laboratories Inc.
    • 6.1.5 Danaher Corporation
    • 6.1.6 GE Healthcare
    • 6.1.7 Merck KGaA
    • 6.1.8 PerkinElmer Inc.
    • 6.1.9 Tecan Group Ltd
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS